Genetically engineered insulin analogs: diabetes in the new millenium.
暂无分享,去创建一个
[1] S. Genuth,et al. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. , 1993, The New England journal of medicine.
[2] U. Ribel,et al. Albumin binding of insulins acylated with fatty acids: characterization of the ligand-protein interaction and correlation between binding affinity and timing of the insulin effect in vivo. , 1995, The Biochemical journal.
[3] L. Heinemann,et al. Insulin Aspart in a 30/70 Premixed Formulation: Pharmacodynamic properties of a rapid-acting insulin analog in stable mixture , 1997, Diabetes Care.
[4] B. Zinman,et al. Insulin Lispro in CSII: Results of a Double-Blind Crossover Study , 1997, Diabetes.
[5] S. Gammeltoft,et al. Receptor Binding and Tyrosine Kinase Activation by Insulin Analogues With Extreme Affinities Studied in Human Hepatoma HepG2 Cells , 1991, Diabetes.
[6] D. Brems,et al. Improved insulin stability through amino acid substitution. , 1992, Protein engineering.
[7] L. Vignati,et al. Reduction of postprandial hyperglycemia and frequency of hypoglycemia in IDDM patients on insulin-analog treatment. Multicenter Insulin Lispro Study Group. , 1997 .
[8] L. Heinemann,et al. Do Insulin‐treated Diabetic Patients Use an Injection‐meal‐interval in Daily Life? , 1995, Diabetic medicine : a journal of the British Diabetic Association.
[9] L. Heinemann,et al. Variability of the metabolic effect of soluble insulin and the rapid-acting insulin analog insulin aspart. , 1998, Diabetes care.
[10] L. Vignati,et al. Reduction of Postprandial Hyperglycemia and Frequency of Hypoglycemia in IDDM Patients on Insulin-Analog Treatment , 1997, Diabetes.
[11] H. Klein,et al. Sustained signalling from the insulin receptor after stimulation with insulin analogues exhibiting increased mitogenic potency. , 1996, The Biochemical journal.
[12] R. Landgraf,et al. Use of insulin lispro in continuous subcutaneous insulin infusion treatment. Results of a multicenter trial. German Humalog-CSII Study Group. , 1999, Diabetes care.
[13] Abstract , 1952 .
[14] A. Vaag,et al. NovoSol Basal: pharmacokinetics of a novel soluble long acting insulin analogue. , 1989, BMJ.
[15] F. Shojaee-Moradie,et al. Novel hepatoselective insulin analogues: studies with covalently linked thyroxyl‐insulin complexes , 1998, Diabetic medicine : a journal of the British Diabetic Association.
[16] D. Howey,et al. Biosynthetic Human Proinsulin: Review of Chemistry, in Vitro and in Vivo Receptor Binding, Animal and Human Pharmacology Studies, and Clinical Trial Experience , 1992, Diabetes Care.
[17] M. Trautmann,et al. Intensive insulin therapy with insulin lispro in patients with type 1 diabetes reduces the frequency of hypoglycemic episodes. , 2009, Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association.
[18] M. Trautmann,et al. Severe insulin resistance treated with insulin lispro , 1996, The Lancet.
[19] P. Brunetti,et al. Use of the short‐acting insulin analogue lispro in intensive treatment of Type 1 diabetes mellitus: importance of appropriate replacement of basal insulin and time‐interval injection‐meal , 1998, Diabetic medicine : a journal of the British Diabetic Association.
[20] P. Brunetti,et al. Contribution of postprandial versus interprandial blood glucose to HbA1c in type 1 diabetes on physiologic intensive therapy with lispro insulin at mealtime. , 1999, Diabetes care.
[21] O Faber,et al. Insulin Pharmacokinetics , 1984, Diabetes Care.
[22] Warszawski Uniwersytet Medyczny,et al. Diabetes care , 2019, Health at a Glance.
[23] M. Davidson,et al. The Variability in the Action of Unmodified Insulin is More Dependent on Changes in Tissue Insulin Sensitivity than on Insulin Absorption , 1988, Diabetic medicine : a journal of the British Diabetic Association.
[24] B. Zinman,et al. Stability of Insulin Lispro in Insulin Infusion Systems , 1997, Diabetes Care.
[25] M. Burge,et al. Optimal administration of lispro insulin in hyperglycemic type 1 diabetes. , 1999, Diabetes care.
[26] N. Fineberg,et al. Immunologic Effects of Insulin Lispro [Lys (B28), Pro (B29) Human Insulin] in IDDM and NIDDM Patients Previously Treated With Insulin , 1996, Diabetes.
[27] P. Home,et al. Improved glycemic control with insulin aspart: a multicenter randomized double-blind crossover trial in type 1 diabetic patients. UK Insulin Aspart Study Group. , 1998, Diabetes care.
[28] A. Lindholm,et al. Improved postprandial glycemic control with insulin aspart. A randomized double-blind cross-over trial in type 1 diabetes. , 1999, Diabetes care.
[29] S. R. Myers,et al. Acylation of Human Insulin With Palmitic Acid Extends the Time Action of Human Insulin in Diabetic Dogs , 1997, Diabetes.
[30] J. Rosenstock,et al. Efficacy and Safety of HOE 901 (Insulin Glargine) in Subjects with Type 2 DM: A 28-Week Randomized, NPH Insulin-Controlled Trial , 1999 .
[31] P. Brunetti,et al. Long-term intensive treatment of type 1 diabetes with the short-acting insulin analog lispro in variable combination with NPH insulin at mealtime. , 1999, Diabetes care.
[32] L. Slieker,et al. Insulin and IGF-I analogs: novel approaches to improved insulin pharmacokinetics. , 1993, Advances in experimental medicine and biology.
[33] H. Häring,et al. The long acting human insulin analog HOE 901: characteristics of insulin signalling in comparison to Asp(B10) and regular insulin. , 1998, Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme.
[34] W. Duckworth,et al. Differences in the cellular processing of AspB10 human insulin compared with human insulin and LysB28ProB29 human insulin. , 1999, Metabolism: clinical and experimental.
[35] S. Havelund,et al. Effect of fatty acids and selected drugs on the albumin binding of a long-acting, acylated insulin analogue. , 1997, Journal of pharmaceutical sciences.
[36] Gareth R. Williams,et al. Severe insulin resistance treated with insulin lispro , 1997, The Lancet.
[37] H. Chase,et al. Long‐term efficacy of Humalogã in subjects with Type 1 diabetes mellitus , 1999, Diabetic medicine : a journal of the British Diabetic Association.
[38] K. Drejer. The bioactivity of insulin analogues from in vitro receptor binding to in vivo glucose uptake. , 1992, Diabetes/metabolism reviews.
[39] L. Vignati,et al. Health-Related Quality-of-Life Results From Multinational Clinical Trials of Insulin Lispro: Assessing benefits of a new diabetes therapy , 1997, Diabetes Care.
[40] M. Knip,et al. Severe Antibody-Mediated Human Insulin Resistance: Successful Treatment With the Insulin Analog Lispro: A case report , 1997, Diabetes Care.
[41] M. Trautmann,et al. Improved postprandial blood glucose control and reduced nocturnal hypoglycemia during treatment with two novel insulin lispro-protamine formulations, insulin lispro mix25 and insulin lispro mix50. Mix50 Study Group. , 1999, Clinical therapeutics.
[42] William V Tamborlane,et al. Comparison of Human Regular and Lispro Insulins After Interruption of Continuous Subcutaneous Insulin Infusion and in the Treatment of Acutely Decompensated IDDM , 1998, Diabetes Care.
[43] Y. Shechter,et al. New concept for long-acting insulin: spontaneous conversion of an inactive modified insulin to the active hormone in circulation: 9-fluorenylmethoxycarbonyl derivative of insulin. , 1999, Diabetes.
[44] P. Katsoyannis,et al. A superactive insulin : [ B 10-Aspartic acid ] insulin ( human ) ( insulin analogue / peptide synthesis / biological activity ) , 2022 .
[45] W. Duckworth. Tumor necrosis factor and insulin resistance: specificity of sequence accounts of inhibition of insulin action. , 1997, The Journal of laboratory and clinical medicine.
[46] Novel Hepatoselective Insulin Analog , 2001 .
[47] D. Howey,et al. [Lys(B28), Pro(B29)]-Human Insulin: A Rapidly Absorbed Analogue of Human Insulin , 1994, Diabetes.
[48] M. Berger. Towards more physiological insulin therapy in the 1990s. A comment. , 1989, Diabetes research and clinical practice.
[49] D. Leroith,et al. Current Directions in Insulin-Like Growth Factor Research , 2013, Advances in Experimental Medicine and Biology.
[50] M. Lavelle-Jones,et al. Selective suppression of hepatic glucose output by human proinsulin in the dog. , 1987, The American journal of physiology.
[51] J. M. Beals,et al. LYS(B28)PRO(B29)-HUMAN INSULIN , 1996 .
[52] D. Cohen,et al. Metabolically inactive insulin analog prevents type I diabetes in prediabetic NOD mice. , 1997, The Journal of clinical investigation.
[53] D. Rogers,et al. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus , 1994 .
[54] R. Heine,et al. Nighttime Insulin Kinetics and Glycemic Control in Type 1 Diabetes Patients Following Administration of an Intermediate-Acting Lispro Preparation , 1997, Diabetes Care.
[55] V. Koivisto,et al. Meta-Analysis of the Effect of Insulin Lispro on Severe Hypoglycemia in Patients With Type 1 Diabetes , 1998, Diabetes Care.
[56] L. Vignati,et al. Basal activity profiles of NPH and [Nɛ-palmitoyl Lys (B29)] human insulins in subjects with IDDM , 1998, Diabetologia.
[57] K. Polonsky,et al. The Effects of Biosynthetic Human Proinsulin on Carbohydrate Metabolism , 1984, Diabetes.
[58] J. Brange,et al. Monomeric insulins obtained by protein engineering and their medical implications , 1988, Nature.
[59] L. Heinemann,et al. Time‐action profile of the soluble, fatty acid acylated, long‐acting insulin analogue NN304 , 1999, Diabetic medicine : a journal of the British Diabetic Association.
[60] F. Matsuzaki,et al. GROWTH-PROMOTING AND METABOLIC EFFECTS OF GROWTH HORMONE. , 1964, Metabolism: clinical and experimental.
[61] G. Park,et al. Long-acting insulin analogs. , 1999, Diabetes care.